Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
17.04
+0.25 (1.49%)
At close: May 12, 2025, 4:00 PM
17.50
+0.46 (2.70%)
After-hours: May 12, 2025, 6:16 PM EDT
Castle Biosciences Employees
Castle Biosciences had 761 employees as of December 31, 2024. The number of employees increased by 151 or 24.75% compared to the previous year.
Employees
761
Change (1Y)
151
Growth (1Y)
24.75%
Revenue / Employee
$456,088
Profits / Employee
-$6,661
Market Cap
491.98M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CSTL News
- 3 days ago - Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result - GlobeNewsWire
- 5 days ago - Castle Biosciences Celebrates Skin Cancer Awareness Month - GlobeNewsWire
- 7 days ago - Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Castle Biosciences Reports First Quarter 2025 Results - GlobeNewsWire
- 7 days ago - Castle Biosciences to Acquire Previse - GlobeNewsWire
- 10 days ago - New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer - GlobeNewsWire
- 12 days ago - New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - GlobeNewsWire
- 14 days ago - DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma - GlobeNewsWire